10/526025
BT01 Rec'd PCT/PTO 28 FEB 2005

AMENDMENTS TO THE CLAIMS

1 (Currently amended). A method of treatment of a patient in need of modulation of body mass or modulation of increase in body mass, and/or in need of modulation of plasma insulin, plasma glucose, plasma triglycerides and/or plasma cholesterol, comprising

administering to the patient an effective amount of a compound comprising perfluorooctanoic acid or a salt ~~(preferably other than ammonium salt, preferably other than 75% straight chain ammonium salt)~~ or an ester thereof[;] , perfluorosuberic acid, perfluoroheptanoic acid, perfluorohexanoic acid, perfluoropentanoic acid, perfluorobutanoic acid or perfluoropropionic acid or a salt or an ester any thereof[;] , or perfluorooctane.

2 (Currently amended). ~~A~~ The method of claim 1 ~~of treatment of a~~

wherein the patient is in need of an antitumour agent or an antiinflammatory agent, or in need of modulation in lipid or eicosanoid status~~, comprising administering to the patient an effective amount of a compound as defined in claim 1~~.

3 (Currently amended). ~~A~~ The method of claim 1 ~~of treatment of a~~

wherein the patient ~~who~~ is overweight or obese and/or has diabetes, hyperlipidaemia, atherosclerosis, coronary heart disease, stroke, obstructive sleep apnoea, arthritis and/or reduced fertility, or is at risk of developing such a condition~~, comprising administering to the patient an effective amount of a compound as defined in claim 1~~.

4 (Currently amended). ~~A~~ The method of claim 1 ~~of treatment of a~~

wherein the patient is in need of modulation of PPAR ~~(for example PPARα)~~ activity~~, comprising administering to the patient an effective amount of a compound as defined in claim 1~~.

5 (Canceled).

6 (Currently amended). ~~Use of a compound as defined in claim 1 in the manufacture of~~ A method of manufacturing a medicament for treating a patient as defined in claim 1 ~~in need of modulation of PPAR (for example PPARα) activity~~ comprising

using a compound as defined in claim 1.

7 (Currently amended). The method of claim 4 ~~or use of claim 6~~

wherein the patient is in need of an increase in PPAR activity and the compound is a PPAR agonist.

8 (Currently amended). The method ~~or use~~ of claim 7

wherein the PPAR is PPARα or PPARγ.

9 (Currently amended). ~~The use of a compound as defined in claim 1 in the manufacture of a medicament for the treatment of a~~ The method of claim 6

wherein the medicament is for the treatment of a patient in need of modulation of body mass or modulation of increase in body mass, and/or in need of modulation of plasma insulin, plasma glucose, plasma triglycerides and/or plasma cholesterol.

10 (Currently amended). The method of claim 1 ~~or use of claim 9~~

wherein the patient is in need of reduction of body mass or prevention of increase in body mass, and/or in need of reduction of plasma insulin, plasma glucose, plasma triglycerides and/or plasma cholesterol.

11 (Currently amended). ~~The use of a compound as defined in claim 1 in the manufacture of~~ The method of claim 6 ~~a~~

wherein the medicament is for the treatment of a patient who is overweight or obese and/or has diabetes, hyperlipidaemia, atherosclerosis, coronary heart disease, stroke, obstructive sleep apnoea, arthritis and/or reduced fertility, or is at risk of developing such a condition.

12 (Currently amended). ~~The use of a compound as defined in claim 1 in the manufacture of~~ The method of claim 6 ~~a~~

wherein the medicament is for the treatment of a patient in need of an antitumour agent or an antiinflammatory agent or of modulation of lipid or eicosanoid status or function, or of modulation of a lipid metabolising or binding entity activity.

13 (Currently amended). The method of ~~treatment or use of any one of~~ claims 1 ~~to 12~~

wherein the compound is or comprises a perfluorooctanoic acid, or is more than 75% ~~(for example 80%, 90% or 100%)~~ linear perfluorooctanoic acid or a salt or ester thereof.

14 (Currently amended). The method of ~~treatment or use of any one of~~ claims 1 ~~to 12,~~

wherein the compound is or comprises a perfluoroheptanoic acid or salt or ester thereof.

15 (Currently amended). The ~~compound,~~ method ~~or use of any one~~ of claims 1 ~~to 12~~

wherein the compound is a perfluoropentanoic acid or salt or ester thereof.

16 (Canceled).

17 (Currently amended). A screening method for identifying a drug-like compound or lead compound for the development of a drug-like compound comprising ~~in which (1)~~

exposing a mammal ~~is exposed~~ to a compound as defined in claim 1 or derivative thereof, and

~~(2)~~ measuring at least one of the plasma insulin, glucose, cholesterol, ~~and/or~~ triglyceride ~~level of the mammal is measured, and/or~~ bodyweight ~~of the mammal is measured~~, and~~/or~~ lipid or eicosanoid status or function of the mammal ~~is measured~~.

18 (Currently amended). The method of claim 17, further comprising

the step of selecting a compound on exposure to which the plasma insulin, glucose, cholesterol and/or triglyceride level of the mammal is changed or reduced, and/or bodyweight or bodyweight increase of the mammal is changed or reduced.

19 (Currently amended). A screening method for identifying a drug-like compound or lead compound for the development of a drug-like compound comprising ~~in which (1)~~

exposing a compound as defined in claim 1 or derivative thereof ~~is exposed~~ to a PPAR polypeptide, and

~~(2) the~~ measuring at least one of binding of the compound to the PPAR polypeptide ~~is measured~~ or the change in the activity of the PPAR polypeptide ~~is measured~~.

20 (Currently amended). A screening method for identifying a drug-like compound or lead compound for the development of a drug-like compound comprising ~~in which (1)~~

exposing a compound as defined in claim 1 or derivative thereof ~~is exposed~~ to a lipid metabolising or binding entity, ~~for example cycloxygenase (for example cyclooxygenase I or cyclooxygenase II) or phospholipase A (for example phospholipase A2)~~ and

~~(2)~~ measuring at least one of the binding of the compound to the lipid metabolising or binding entity ~~is measured~~ or the change in the activity of the lipid metabolising or binding entity ~~is measured~~.

21 (Currently amended). A screening method for identifying a drug-like compound or lead compound for the development of a drug-like compound comprising ~~in which (1)~~

exposing a cell ~~is exposed~~ to a compound as defined in claim 1, and

~~(2)~~ measuring at least one of the phenotype ~~(for example differentiation)~~ and~~/or~~ the eicosanoid biosynthesis of the cell ~~is measured~~.

22 (Currently amended). The method of claim 21, further comprising

the step of selecting a compound on exposure to which at least one of the phenotype~~, for~~

~~example differentiation,~~ of the cell ~~is changed, and/~~or the eicosanoid biosynthesis of the cell is changed~~, preferably reduced~~.

23 (Currently amended). The ~~use or~~ method of ~~any one~~ of claims 1 ~~to 12~~

wherein the compound is identified or identifiable by ~~a~~ the screening method of ~~any one of~~ claims 17 ~~to 22~~.

24 (Canceled).

25 (Currently amended). A food product comprising

a foodstuff, and

a compound as defined in claim 1 ~~or a compound identified or identifiable by a screening method of any one of claims 17 to 22, wherein the food is not laboratory rodent feed~~.

26 (Currently amended). A kit of parts of screening system comprising

~~(1)~~ a library of compounds each as defined in claim 1, and

~~(2)~~ a PPAR polypeptide or polynucleotide encoding a PPAR polypeptide, and/or a test mammal.

27 (Currently amended). A kit of parts of screening system comprising

~~(1)~~ a library of compounds each as defined in claim 1, and

~~(2)~~ at least one of a lipid metabolising or binding entity ~~(for example COXI or COXII or phospholipase A2 or lipoxygenase)~~ or a polynucleotide encoding a lipid metabolising or binding entity.

28 (Canceled).

29 (New). A method as in claim 4

wherein the PPAR activity is PPARα activity.

30 (New). A method as in claim 6

wherein the medicament is for the treatment of a patient in need of modulation of PPAR activity.

31 (New). A method as in claim 30

wherein the PPAR activity is PPARα activity.

32 (New). A method as in claim 30

wherein the medicament is for the treatment of a patient in need of an increase in PPAR activity and the compound is a PPAR agonist.

33 (New). The method of claim 6

wherein the medicament is for the treatment of a patient in need of reduction of body mass or prevention of increase in body mass, and/or in need of reduction of plasma insulin, plasma glucose, plasma triglycerides and/or plasma cholesterol.

34 (New). The method of claim 1

wherein the compound is identified or identifiable by the screening method of claim 19.

35 ((New). The method of claim 1

wherein the compound is identified or identifiable by the screening method of claim 20.

36 (New). The method of claim 1

wherein the compound is identified or identifiable by the screening method of claim 21.

37 (New). A food product as in claim 25

wherein the foodstuff is not laboratory rodent feed.